UNSPSC 51311603: Mepyramine or pyrilamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H23N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HPE317O9TL, chemically known as 1,2-ethanediamine, n-((4-methoxyphenyl)methyl)-n,n-dimethyl-n-2-pyridinyl- (9ci) but generally known as mepyramine, which bears US NIH Compound Identifier 4992. European Medicines Agency schedules Mepyramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08762MIG.

UNSPSC 51311603 Mepyramine or pyrilamine is a Commodity code that in practice captures state and local procurement of pharmaceutical products, including naloxone, generic multi-source medications, and over-the-counter items, rather than the single active ingredient its abstract name suggests. State and local health agencies, cooperative purchasing alliances, and county health departments are the primary issuing bodies, with recent solicitations showing demand for both emergency-response pharmaceuticals (naloxone for opioid overdose reversal) and broader generic medication supply contracts that serve multiple jurisdictions and program participants. The work involves sourcing products through established wholesaler networks, managing product availability and compliance certifications (cGMP, DSCSA, FDA requirements), negotiating pricing structures across multiple format options, and fulfilling quarterly or ongoing deliveries to designated health facilities and programs.

Recent activity spans Florida, Texas, and Minnesota through multistate cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage state interest in restructuring pharmaceutical procurement channels outside traditional pharmacy benefit managers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026; this procurement requires vendor relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and weighted evaluation prioritizing price competitiveness at 75 percent.